Targeting regulatory T cells in tumor immunotherapy

Immunology and Cell Biology

Volumn 92, Issue 6, 2014, Pages 473-474

  Smyth, Mark J ^a,b   Ngiow, Shin Foong ^a   Teng, Michele W L ^a,b  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; FC RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR; TNFRSF4 PROTEIN, MOUSE;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; NONHUMAN; NOTE; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TARGET CELL; TH1 CELL; ANIMAL; EXPERIMENTAL NEOPLASM; IMMUNOLOGY;

ANIMALS; NEOPLASMS, EXPERIMENTAL; RECEPTORS, IGG; RECEPTORS, OX40; T-LYMPHOCYTES, REGULATORY;

EID: 84904057925     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2014.33     Document Type: Note

References (12)

1. Nimmerjahn F, Ravetch JV. Translating basic mechanisms of IgG effector activity into next generation cancer therapies. Cancer Immun 2012; 12: 13.
2. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgRs, leading to antitumor efficacy. Immunol Cell Biol 2014; 92: 475-480.
3. Drake CG, Lipson EJ, Brahmer Jr. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014; 11: 24-37.
4. Teng MW, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010; 70: 7800-7809.
5. Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, McLaughlin N et al. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 2010; 70: 2665-2674.
6. Whiteside TL. What are regulatory T cells (Treg) regulating in cancer and why? Semin Cancer Biol 2012; 22: 327-334.
7. Jacobs JF, Nierkens S, Figdor CG, de Vries IJ, Adema GJ. Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy? Lancet Oncol 2012; 13: e32-e42.
8. Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M et al. Signaling through OX40 enhances antitumor immunity. Semin Oncol 2010; 37: 524-532.
9. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 2013; 210: 1695-1710.
10. Bulliard Y, Jolicoeur R, Windman M, Rue SM, Ettenberg S, Knee DA et al. Activating Fc gamma receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med 2013; 210: 1685-1693.
11. Sakuishi K, Ngiow SF, Sullivan JM, Teng MW, Kuchroo VK, Smyth MJ et al. TIM3FOXP3 regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunol 2013; 2: e23849.
12. Marabelle A, Kohrt H, Levy R. Intratumoral anti-CTLA-4 therapy: enhancing efficacy while avoiding toxicity. Clin Cancer Res 2013; 19: 5261-5263.